All Children's Hospital Selects ValiMed(TM) System for Medication Validation; Developed by CDEX, the ValiMed System was chosen by All Children's to Verify Compounded Medications and Doses, and Validate Narcotic Returns
ROCKVILLE, Md., Mar 14, 2006 (BUSINESS WIRE) -- CDEX, Inc., announced today
that All Children's Hospital in St. Petersburg, Florida has selected the ValiMed
Medication Validation System to perform end-product testing of compounded
intravenous medications in its pharmacy departments, and validation of returned
narcotics in its operating room suites and nursing units. The ValiMed System,
developed by CDEX (CEXI.OB), gives clinicians a quick, cost-effective, and
simple tool to ensure medication safety by verifying medications are correctly
compounded. All Children's Hospital, a 216-bed teaching hospital affiliated with
the University of South Florida College of Medicine, is a leading center for
pediatric treatment, education, and research.
In a process that takes only seconds, the ValiMed System uses patent-pending
technology to validate compounded doses of high-risk medications prior to
dispensing. The system documents the accuracy of the medication dispensing
process, and is used to validate narcotic returns as well as identify
counterfeit medications.
"We are pleased that a nationally recognized institution, such as All Children's
Hospital of Florida, is now using our ValiMed System for medication validation,"
said Jim Griffin, President and CEO of CDEX.
The ValiMed System uses light energy and a library of unique spectral
fingerprints to validate drugs in a solution. The device validates that the
correct drugs in the correct amounts have been added to the dose during the
compounding process. The ValiMed Medication Validation System is distributed
under an exclusive agreement with Baxa Corporation of Englewood, Colorado.
About CDEX, Inc.
CDEX, Inc. is a technology development company with a current focus on
developing and marketing products using chemical detection and validation
technologies. At present, CDEX is devoting its resources to two distinct areas:
(i) identification of substances of concern (e.g., explosives and illegal drugs
for homeland security); and (ii) validation of substances for
anti-counterfeiting, brand protection and quality assurance (e.g., validation of
prescription medication and detection of counterfeit or sub-par products for
brand protection). ValiMed is one line of CDEX products for the healthcare
market. CDEX is headquartered in Rockville, Maryland with its research and
development laboratory in Tucson, Arizona. For more information, visit
www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
CONTACT: CDEX, Inc., Rockville
Media:
Brad Wills, 301-767-1919
bwills@wills-pr.com
Copyright Business Wire 2006
KEYWORD: United States
North America
Maryland
INDUSTRY KEYWORD: Technology
Hardware
Software
Health
Biotechnology
Hospitals
Medical Devices
Pharmaceutical
Other Health
Professional Services
Legal
SUBJECT CODE: Product/Service
|
